Australia's most trusted
source of pharma news
Posted 20 October 2025 PM
It's been hailed as a new era in treatment for breast cancer patients, but the grim reality is that a punishing 650 day wait for a PBS listing for Lilly's Verzenio, left 3500 Australian women without funded access to the drug.
According to seven-year data from the landmark monarchE trial, two years of treatment with Verzenio in combination with endocrine therapy (ET) reduces the relative risk of death by 15.8 per cent compared to ET alone in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), node- positive, high-risk early breast cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.